ClinicalTrials.gg
TerminatedNCT01687478Updated Oct 9, 2019Results posted

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

A Phase 3 interventional study of Olanzapine and Fluoxetine in Treatment Resistant Depression, sponsored by Eli Lilly and Company. Terminated at 11 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
Interim assessment: Lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Depressive Disorder, Treatment-Resistant with a site in China — 13 open to participants now, 14 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · China.

Enrollment
7th of 29
176 · median 60
Started
2012
the only one that year
Phase 3
3 of 30
1 open now
Registered
1st of 30
by date
Lead sponsor
1 of 30
Eli Lilly and Company

Among the 30 studies in Depressive Disorder, Treatment-Resistant with a site in China, this one is the 7th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 3, and was the 1st registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

13 of the 30 studies in Depressive Disorder, Treatment-Resistant with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Depressive Disorder, Treatment-Resistant with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have single or recurrent unipolar major depressive disorder (MDD) without psychotic features by , Fourth Edition-Text Revision (DSM-IV-TR) clinical assessment
  • Have a total score ≥22 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at screening and randomization
  • Have treatment-resistant depression (TRD), defined as having failed to achieve a satisfactory antidepressant response, in the opinion of the investigator, to separate treatment courses of at least 2 different antidepressants, other than fluoxetine, of adequate dosage and duration (≥6 weeks) within the current major depressive episode

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of Parkinson's disease or a related disorder
  • Have a current or lifetime diagnosis of any of the following conditions, according to criteria: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified; Bipolar Disorder I or II; Delirium of any type; Dementia of any type; Amnestic Disorder; any Substance-Induced Disorder; or any Psychotic Disorder due to a General Medical Condition
  • Have a current diagnosis of post-partum depression or MDD with a seasonal pattern as defined in the DSM-IV-TR
  • Have paranoid, schizoid, schizotypal, antisocial, or borderline personality disorder (Axis II) as a comorbid or primary diagnosis, based on DSM-IV-TR criteria
  • Have DSM-IV-TR substance dependence/abuse or are not willing to avoid use of the substance (not including dependence on nicotine or caffeine) within 30 days of screening
  • Are actively suicidal in the judgment of the investigator
  • Have uncorrected narrow-angle glaucoma
  • Have had one or more seizures without a clear and resolved etiology
  • Have leukopenia
  • Have any acute, serious, or unstable medical conditions
  • Have an increased serum prolactin concentration at screening
  • Have a rate-corrected cardiac , calculated using Bazett's formula (QTc Bazett's [Rate-corrected cardiac QT interval on calculated using Bazett's formula(QTcB)]), on Electrocardiogram (ECG) >450 milliseconds (male) or >470 milliseconds (female) at screening
  • Have a history of allergic reaction to olanzapine, fluoxetine, or olanzapine in combination with fluoxetine
  • Have had treatment with olanzapine, fluoxetine, or olanzapine in combination with fluoxetine withdrawn due to and/or intolerable adverse effects within 6 months of screening
  • Have received treatment with remoxipride within 6 months of randomization
  • Have received treatment with depot antipsychotics within one dosing interval before randomization
  • Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) treatment within the current MDD episode, or has a history of failure to respond to adequate treatment courses of ECT or VNS, or is expected to require ECT or VNS at any time during the study
  • Have received previous treatment with clozapine
  • Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of screening, or are expected to need MAOI treatment at any time during the study or up until 5 weeks after study discontinuation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Olanzapine + Fluoxetine

    Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks. Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.

    Drug: Olanzapine · Drug: Fluoxetine

  • Placebo comparator
    Placebo + Fluoxetine

    Placebo matches the Olanzapine tablet for blinding. Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.

    Drug: Fluoxetine · Drug: Placebo

Interventions

  • Administered Orally

    Also known as: LY170053, Zyprexa

  • Administered Orally

    Also known as: LY110140, Prozac

  • DrugPlacebo

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)

    The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. Least square means (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for treatment, Pooled Investigator, Visit, (Baseline + Treatment)\*Visit.

    Time frame: Baseline, 8 Weeks

Secondary outcomes

  1. Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale

    CGI-S scale measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The LS mean (LSM) change from baseline, standard error was derived using MMRM methodology with factors for treatment , Pooled Investigator , Visit , (Baseline + Treatment)\*Visit.

    Time frame: Baseline, 8 Weeks

  2. Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)

    SAS scale consists of 10 items including 7 items that address bradykinesia-rigidity and additional single items for tremor, glabellar tap,and salivation. Each item represents a specific physical condition and is rated on a 5-point category rating scale ranging from 0 (complete absence of the condition) to 4 (the condition is present to an extreme degree).The total score is obtained by adding the scores for the 10 individual items making the maximum possible score is 40. Higher scores are indicative of more severe Parkinsonian-type symptoms.

    Time frame: Baseline, 8 Weeks

  3. Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)

    SF-36, version 2 is a generic participant-rated questionnaire and consists of 36 questions covering the following 8 health domains (subscales): general health, role limitations because of physical problems, role limitations due to emotional problems, physical functioning, bodily pain, mental health, social functioning, and vitality. Each subscale is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) were constructed based on the eight SF-36 subscales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.

    Time frame: Baseline, 8 Weeks

  4. Mean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)

    SDS consists of 3 items (work/school, social life/leisure activities, and family life/home responsibilities). Total scores range from 0 to 30 with higher values indicating greater disruption. Individual Item scores range from 0 to 10 with higher values indicating greater disruption.

    Time frame: Baseline, 8 Weeks

  5. Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score

    The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.

    Time frame: Baseline,8 Weeks

  6. Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks

    The MADRS consists of 10 items with each item rated on a scale ranging from 0 to 6. Fixed descriptors appear along the scale for each item at points 0, 2, 4, and 6, to standardize the gradation of response along the scale. The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.

    Time frame: Baseline, 8 Weeks

  7. Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)

    BAS is used to rate observable, restless movements of drug induced akathisia and the subjective awareness of restlessness and any distress associated with the akathisia. The BAS consists of the following 3 items: an objective assessment of akathisia symptoms; a subjective assessment of the patient's awareness of inner restlessness; and a global clinical assessment of akathisia. The first two items are rated on a 4-point scale ranging from 0 (no abnormal movements or the absence of inner restlessness) to 3 (severe akathisia or the awareness of intense compulsion to move most of the time). The last item, the global clinical assessment of akathisia, is rated on a 5-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Total BAS score ranges from 0 to 14 with a higher score representing worse results.

    Time frame: Baseline, 8 Weeks

  8. Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)

    AIMS is a 12-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 and 12 are yes/no questions regarding the dental status of the participant. The total score is the sum of the scores for the 12 items and the possible total score ranges from 0 to 42. A higher total score is indicative of more severe dyskinetic movements.

    Time frame: Baseline, 8 Weeks

07

Results

Posted Aug 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneOlanzapine + FluoxetinePlacebo + Fluoxetine
Started8888
Safety analysis set8887
Completed5649
Not completed3239
Withdrew: Adverse event310
Withdrew: Lost to follow-up13
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject2119
Withdrew: Physician decision13
Withdrew: Entry criteria not met62

Outcome measures

PrimaryMean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)

The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. Least square means (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for treatment, Pooled Investigator, Visit, (Baseline + Treatment)\*Visit.

Time frame:
Baseline, 8 Weeks
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)
Units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)-15.92 ± 1.20-14.30 ± 1.28
Statistical analysis
  • Olanzapine + Fluoxetine vs Placebo + Fluoxetine · Mean difference (net): -1.62 · 95% CI -5.04 to 1.80The Confidence Interval is based on the treatment difference LS Mean changes from baseline between Olanzapine + Fluoxetine and Placebo + Fluoxetine.
SecondaryMean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale

CGI-S scale measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The LS mean (LSM) change from baseline, standard error was derived using MMRM methodology with factors for treatment , Pooled Investigator , Visit , (Baseline + Treatment)\*Visit.

Time frame:
Baseline, 8 Weeks
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale
Units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale-1.43 ± 0.15-1.63 ± 0.16
SecondaryMean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)

SAS scale consists of 10 items including 7 items that address bradykinesia-rigidity and additional single items for tremor, glabellar tap,and salivation. Each item represents a specific physical condition and is rated on a 5-point category rating scale ranging from 0 (complete absence of the condition) to 4 (the condition is present to an extreme degree).The total score is obtained by adding the scores for the 10 individual items making the maximum possible score is 40. Higher scores are indicative of more severe Parkinsonian-type symptoms.

Time frame:
Baseline, 8 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)
units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)0.03 ± 1.71-0.14 ± 1.72
SecondaryMean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)

SF-36, version 2 is a generic participant-rated questionnaire and consists of 36 questions covering the following 8 health domains (subscales): general health, role limitations because of physical problems, role limitations due to emotional problems, physical functioning, bodily pain, mental health, social functioning, and vitality. Each subscale is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) were constructed based on the eight SF-36 subscales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.

Time frame:
Baseline, 8 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)
units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Physical Functioning2.20 ± 7.510.70 ± 7.47
Role-Physical3.99 ± 11.793.93 ± 11.23
Bodily Pain6.81 ± 12.050.02 ± 11.30
General Health5.82 ± 11.492.84 ± 9.44
Vitality7.43 ± 13.545.04 ± 9.83
Social Functioning6.13 ± 13.554.56 ± 11.78
Role-Emotional6.61 ± 12.396.71 ± 12.12
Mental Health8.98 ± 13.468.43 ± 11.99
Mental Component Score8.87 ± 14.298.73 ± 12.54
Physical Component Score2.87 ± 7.59-0.65 ± 7.22
SecondaryMean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)

SDS consists of 3 items (work/school, social life/leisure activities, and family life/home responsibilities). Total scores range from 0 to 30 with higher values indicating greater disruption. Individual Item scores range from 0 to 10 with higher values indicating greater disruption.

Time frame:
Baseline, 8 Weeks
Reported as:
Mean · Units on a scale
Mean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)
Units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Work/School (n=68,65)-1.34 ± 2.71-1.55 ± 2.89
Social Life (n=79,79)-1.70 ± 2.66-1.49 ± 2.85
Family Life (n=79,78)-1.63 ± 3.00-1.53 ± 2.66
SDS Total Score (68,64)-4.57 ± 7.75-4.41 ± 7.89
SecondaryPercentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score

The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.

Time frame:
Baseline,8 Weeks
Reported as:
Number · Percent of participants
Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score
Percent of participantsOlanzapine + FluoxetinePlacebo + Fluoxetine
Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score65.561.2
SecondaryPercentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks

The MADRS consists of 10 items with each item rated on a scale ranging from 0 to 6. Fixed descriptors appear along the scale for each item at points 0, 2, 4, and 6, to standardize the gradation of response along the scale. The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms.

Time frame:
Baseline, 8 Weeks
Reported as:
Number · Percent of participants
Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks
Percent of participantsOlanzapine + FluoxetinePlacebo + Fluoxetine
Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks37.938.8
SecondaryMean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)

BAS is used to rate observable, restless movements of drug induced akathisia and the subjective awareness of restlessness and any distress associated with the akathisia. The BAS consists of the following 3 items: an objective assessment of akathisia symptoms; a subjective assessment of the patient's awareness of inner restlessness; and a global clinical assessment of akathisia. The first two items are rated on a 4-point scale ranging from 0 (no abnormal movements or the absence of inner restlessness) to 3 (severe akathisia or the awareness of intense compulsion to move most of the time). The last item, the global clinical assessment of akathisia, is rated on a 5-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Total BAS score ranges from 0 to 14 with a higher score representing worse results.

Time frame:
Baseline, 8 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)
units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)-0.01 ± 2.24-0.04 ± 2.13
SecondaryMean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)

AIMS is a 12-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 and 12 are yes/no questions regarding the dental status of the participant. The total score is the sum of the scores for the 12 items and the possible total score ranges from 0 to 42. A higher total score is indicative of more severe dyskinetic movements.

Time frame:
Baseline, 8 Weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
units on a scaleOlanzapine + FluoxetinePlacebo + Fluoxetine
Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)-0.16 ± 1.47-0.31 ± 3.28

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine + Fluoxetine—1/88 (1.1%)55/88 (62.5%)
Placebo + Fluoxetine—1/87 (1.1%)45/87 (51.7%)
Most frequent serious events
Most frequent serious events
EventOlanzapine + FluoxetinePlacebo + Fluoxetine
Suicide attemptPsychiatric disorders0/881/87
RestlessnessPsychiatric disorders1/880/87
Most frequent other events
Showing 10 of 84
Most frequent other events
EventOlanzapine + FluoxetinePlacebo + Fluoxetine
SomnolenceNervous system disorders15/883/87
Blood prolactin increasedInvestigations9/882/87
Weight increasedInvestigations8/882/87
Alanine aminotransferase increasedInvestigations7/881/87
Blood triglycerides increasedInvestigations7/883/87
Hepatic function abnormalHepatobiliary disorders6/881/87
Increased appetiteMetabolism and nutrition disorders6/881/87
DizzinessNervous system disorders3/885/87
Aspartate aminotransferase increasedInvestigations5/880/87
Blood cholesterol increasedInvestigations5/881/87

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Mean38.63 ± 12.1841.45 ± 12.4440.04 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Female413677
Male475299
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Hispanic or Latino000
Not Hispanic or Latino8888176
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
American Indian or Alaska Native000
Asian8888176
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
China8888176
Montgomery-Äsberg Depression Rating Scale (MADRS) Total Score
Montgomery-Äsberg Depression Rating Scale (MADRS) Total Score(units on a scale)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Mean32.1 ± 5.331.8 ± 4.832.0 ± 5.0
17 Item Hamilton Rating Scale for Depression (HAM-D17) Total Score
17 Item Hamilton Rating Scale for Depression (HAM-D17) Total Score(units on a scale)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Mean24.6 ± 2.625.0 ± 2.624.8 ± 2.6
Clinical Global Impressions-Severity of Depression (CGI-S)
Clinical Global Impressions-Severity of Depression (CGI-S)(units on a scale)Olanzapine + FluoxetinePlacebo + FluoxetineTotal
Mean4.9 ± 0.64.9 ± 0.74.9 ± 0.7

5 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baoding, 071000, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100088, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510080, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310009, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kunming, 650032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210029, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wuhan, 430022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710061, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xinxiang, 453002, China
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 19, 2012
Start
Sep 2012
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Aug 24, 2017
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01687478
Responsible party
Sponsor
First posted
Sep 19, 2012
Start date
Sep 2012
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Aug 24, 2017
Last update
Oct 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion